Author

Chun Wu

THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Chun Wu  et al.

ASSOCIATION BETWEEN ABSOLUTE LYMPHOCYTE COUNT AND OZANIMOD EFFICACY AND SAFETY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY
ASSOCIATION BETWEEN ABSOLUTE LYMPHOCYTE COUNT AND OZANIMOD EFFICACY AND SAFETY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY

Chun Wu  et al.

IMPACT OF OZANIMOD ON FECAL CALPROTECTIN LEVELS AND THE ASSOCIATION WITH OZANIMOD EFFICACY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY
IMPACT OF OZANIMOD ON FECAL CALPROTECTIN LEVELS AND THE ASSOCIATION WITH OZANIMOD EFFICACY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY

Chun Wu  et al.

OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH
OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH

Chun Wu  et al.

EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY
EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY

Chun Wu  et al.

OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH
OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH

Chun Wu  et al.

Item 1 - 6 / 6
1